Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
CD3 × CD20 bispecific T-cell engager (specialist)

Epcoritamab

Brand names: Tepkinly

Epcoritamab is a bispecific monoclonal antibody used to treat certain relapsed or refractory large B-cell lymphomas.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds CD3 on T cells and CD20 on B cells simultaneously, bringing T cells into contact with malignant B cells to trigger T-cell-mediated cytotoxicity.

Prescribing in practice

  • Cytokine release syndrome is an important risk, so step-up dosing and monitoring are used at initiation, typically under specialist supervision with the SPC followed closely.
  • Immune effector cell-associated neurotoxicity and serious infections can occur and require vigilance.
  • It is given by subcutaneous injection under specialist haemato-oncology care.

Monitoring

Monitor for cytokine release syndrome, neurological symptoms and infection, particularly during the step-up dosing period.

Counselling the patient

  • Report fever, chills, confusion or breathlessness urgently, especially in the early weeks.
  • Attend all monitoring appointments closely during the initial dosing phase.

Evidence & guidelines

Epcoritamab is supported by trial evidence in relapsed or refractory large B-cell lymphoma and is appraised by NICE within its licensed indication.

Reference: NICE TA evaluation; BSH guidelines; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways